title: Oral capecitabine to prevent recurrent cutaneous squamous cell carcinoma in a lung transplant recipient.
authors.affiliation: Department of Oncology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Sameer A
authors.initials: SA
authors.lastname: Parikh
authors.forename: Svetomir N
authors.initials: SN
authors.lastname: Markovic
authors.affiliation: Department of Dermatology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Jerry D
authors.initials: JD
authors.lastname: Brewer
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000069287:Capecitabine / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000175:diagnosis / Q000503:physiopathology / Q000601:surgery; D019520:Living Donors; D016040:Lung Transplantation / Q000009:adverse effects* / Q000379:methods; D012086:Reoperation / Q000379:methods; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000209:etiology* / Q000517:prevention & control; D014181:Transplantation Immunology / Q000502:physiology; D016896:Treatment Outcome
chemical_list: D000069287:Capecitabine